SGHT

Company Overview — What Does Sight Sciences, Inc. Do?

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California. Sight Sciences, Inc. (SGHT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Paul Badawi and employs approximately 210 people. With a market capitalization of $198M, SGHT is one of the notable companies in the Healthcare sector.

Sight Sciences, Inc. (SGHT) Stock Rating — Reduce (April 2026)

As of April 2026, Sight Sciences, Inc. receives a Reduce rating with a composite score of 34.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SGHT ranks #3,790 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Sight Sciences, Inc. ranks #638 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SGHT Stock Price and 52-Week Range

Sight Sciences, Inc. (SGHT) currently trades at $3.63. The stock gained $0.13 (3.7%) in the most recent trading session. The 52-week high for SGHT is $9.24, which means the stock is currently trading -60.7% from its annual peak. The 52-week low is $2.03, putting the stock 78.8% above its annual trough. Recent trading volume was 175K shares, suggesting relatively thin trading activity.

Is SGHT Overvalued or Undervalued? — Valuation Analysis

Sight Sciences, Inc. (SGHT) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.96x, versus the sector average of 2.75x. The price-to-sales ratio is 2.45x, compared to 1.66x for the average Healthcare stock.

At current multiples, Sight Sciences, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Sight Sciences, Inc. Profitability — ROE, Margins, and Quality Score

Sight Sciences, Inc. (SGHT) earns a quality factor score of 29/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -70.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -39.3% versus the sector average of -33.1%.

On a margin basis, Sight Sciences, Inc. reports gross margins of 85.3%, compared to 71.5% for the sector. The operating margin is -58.6% (sector: -66.1%). Net profit margin stands at -59.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -6.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SGHT Debt, Balance Sheet, and Financial Health

Sight Sciences, Inc. has a debt-to-equity ratio of 66.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 10.22x, indicating strong short-term liquidity. Total debt on the balance sheet is $42M. Cash and equivalents stand at $92M.

SGHT has a beta of 1.46, meaning it is more volatile than the broader market — a $10,000 investment in SGHT would be expected to move 46.2% more than the S&P 500 on any given day. The stability factor score for Sight Sciences, Inc. is 23/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Sight Sciences, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Sight Sciences, Inc. reported revenue of $77M and earnings per share (EPS) of $-0.74. Net income for the quarter was $-45M. Gross margin was 85.3%. Operating income came in at $-45M.

In FY 2025, Sight Sciences, Inc. reported revenue of $77M and earnings per share (EPS) of $-0.74. Net income for the quarter was $-38M. Gross margin was 86.2%. Revenue grew -3.1% year-over-year compared to FY 2024. Operating income came in at $-37M.

In Q3 2025, Sight Sciences, Inc. reported revenue of $20M and earnings per share (EPS) of $-0.16. Net income for the quarter was $-8M. Gross margin was 86.4%. Revenue grew -1.2% year-over-year compared to Q3 2024. Operating income came in at $-8M.

In Q2 2025, Sight Sciences, Inc. reported revenue of $20M and earnings per share (EPS) of $-0.23. Net income for the quarter was $-12M. Gross margin was 84.8%. Revenue grew -8.5% year-over-year compared to Q2 2024. Operating income came in at $-12M.

Over the past 8 quarters, Sight Sciences, Inc. has demonstrated a growth trajectory, with revenue expanding from $21M to $77M. Investors analyzing SGHT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SGHT Dividend Yield and Income Analysis

Sight Sciences, Inc. (SGHT) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SGHT Momentum and Technical Analysis Profile

Sight Sciences, Inc. (SGHT) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 35/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

SGHT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Sight Sciences, Inc. (SGHT) ranks #638 out of 838 stocks based on the Blank Capital composite score. This places SGHT in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SGHT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SGHT vs S&P 500 (SPY) comparison to assess how Sight Sciences, Inc. stacks up against the broader market across all factor dimensions.

SGHT Next Earnings Date

No upcoming earnings date has been announced for Sight Sciences, Inc. (SGHT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SGHT? — Investment Thesis Summary

The quantitative profile for Sight Sciences, Inc. suggests caution. The quality score of 29/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. High volatility (stability score 23/100) increases portfolio risk.

In summary, Sight Sciences, Inc. (SGHT) earns a Reduce rating with a composite score of 34.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SGHT stock.

Related Resources for SGHT Investors

Explore more research and tools: SGHT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SGHT head-to-head with peers: SGHT vs AZN, SGHT vs SLGL, SGHT vs VMD.